Elexacaftor; 2216712-66-0; VX-445; Elexacaftor [USAN]; RRN67GMB0V; Elexacaftor (USAN); (S)-N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-(2,2,4-trimethylpyrrolidin-1-yl)nicotinamide; 3-Pyridinecarboxamide, N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-((4S)-2,2,4-trimethyl-1-pyrrolidinyl)-; N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide; (6P)-N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide; WJX; ELEXACAFTOR [MI]; UNII-RRN67GMB0V; ELEXACAFTOR [INN]; Elexacaftor (VX-445); ELEXACAFTOR [WHO-DD]; Elexacaftor/Ivacaftor/Tezacaftor; CHEMBL4298128; SCHEMBL20239811; GTPL10552; ELEXACAFTOR [ORANGE BOOK]; DTXSID901027907; EX-A3637; s8851; TRIKAFTA COMPONENT ELEXACAFTOR; VX-445VX-445; WHO 11180; AT16051; DB15444; ELEXACAFTOR COMPONENT OF TRIKAFTA; Compound 1 [WO2018107100A1]; AC-36746; HY-111772; CS-0090942; D11507; A930250; N-(1,3-Dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide